Bacitracin: Difference between revisions
ClaireLewis (talk | contribs) No edit summary |
ClaireLewis (talk | contribs) No edit summary |
||
| (3 intermediate revisions by 2 users not shown) | |||
| Line 1: | Line 1: | ||
==Administration== | ==Administration== | ||
*Type: Topical antibiotic | *Type: Topical [[antibiotic]] | ||
*Dosage Forms: ointment | *Dosage Forms: ointment | ||
*Routes of Administration: topical, IM | *Dosage strengths: 500 unit/g | ||
*Common Trade Names: | *Routes of Administration: topical, ophthalmic, IM | ||
*Common Trade Names: BACiiM, Baciguent, Bacitracin Ophthalmic Ointment | |||
==Adult Dosing== | ==Adult Dosing== | ||
| Line 28: | Line 29: | ||
*Half-life: | *Half-life: | ||
*Metabolism: | *Metabolism: | ||
*Excretion: | *Excretion: Urine 10-40% | ||
==Mechanism of Action== | ==Mechanism of Action== | ||
| Line 39: | Line 40: | ||
==References== | ==References== | ||
*BACiiM (bacitracin) [prescribing information], Horseheads, NY: X-Gen Pharmaceuticals Inc; June 2008. | |||
*Bacitracin (prescribing information). New York, NY: Pharmacia & Upjohn; September 2015. | |||
*Chia JK, Nakata MM, Park SS, et al, “Use of Bacitracin Therapy for Infection Due to Vancomycin-Resistant Enterococcus faecium,” Clin Infect Dis, 1995, 21(6):1520. [PubMed 8749657] | |||
*Cohen SH, Gerding DN, Johnson S, et al, “Clinical Practice Guidelines for Clostridium difficile Infection in Adults: 2010 Update by the Society for healthcare Epidemiology of American (SHEA) and the Infectious Diseases Society of America (IDSA), Infect Control Hosp Epidemiol, 2010, 31(5):431-55. [PubMed 20307191] | |||
*Damm S. Intraoperative anaphylaxis associated with bacitracin irrigation. Am J Health-Syst Pharm. 2011;68(4):323-327. [PubMed 21289327] | |||
*Dudley MN, McLaughlin JC, Carrington G, et al, “Oral Bacitracin vs Vancomycin Therapy for Clostridium difficile-Induced Diarrhea. A Randomized Double-Blind Trial,” Arch Intern Med, 1986, 146(6):1101-4. | |||
*Elsner P, Pevny I, Burg G. Anaphylaxis induced by topically applied bacitracin. Am J Contact Dermat.1990;1:162-164. | |||
<references/> | <references/> | ||
[[Category:Pharmacology]] | [[Category:Pharmacology]] [[Category:ID]] | ||
Latest revision as of 21:29, 19 September 2019
Administration
- Type: Topical antibiotic
- Dosage Forms: ointment
- Dosage strengths: 500 unit/g
- Routes of Administration: topical, ophthalmic, IM
- Common Trade Names: BACiiM, Baciguent, Bacitracin Ophthalmic Ointment
Adult Dosing
- Apply to wound 2-5 times per day
Pediatric Dosing
- Apply to wound 2-5 times per day
- Staph pneumonia/empyema known to be susceptible to bacitracin: 900-1000 units/kg/day IM in 2 to 3 divided doses
Special Populations
- Pregnancy Rating: C
- Lactation risk: Infant risk minimal
- Renal: no adjustment
- Hepatic: No adjustment
Contraindications
- Allergy to class/drug
Adverse Reactions
Serious
- Renal toxicity (IM only)
Common
- Contact dermatitis
Pharmacology
- Half-life:
- Metabolism:
- Excretion: Urine 10-40%
Mechanism of Action
- Interferes with cell wall peptidoglycan activity
- Active against staph
Comments
See Also
References
- BACiiM (bacitracin) [prescribing information], Horseheads, NY: X-Gen Pharmaceuticals Inc; June 2008.
- Bacitracin (prescribing information). New York, NY: Pharmacia & Upjohn; September 2015.
- Chia JK, Nakata MM, Park SS, et al, “Use of Bacitracin Therapy for Infection Due to Vancomycin-Resistant Enterococcus faecium,” Clin Infect Dis, 1995, 21(6):1520. [PubMed 8749657]
- Cohen SH, Gerding DN, Johnson S, et al, “Clinical Practice Guidelines for Clostridium difficile Infection in Adults: 2010 Update by the Society for healthcare Epidemiology of American (SHEA) and the Infectious Diseases Society of America (IDSA), Infect Control Hosp Epidemiol, 2010, 31(5):431-55. [PubMed 20307191]
- Damm S. Intraoperative anaphylaxis associated with bacitracin irrigation. Am J Health-Syst Pharm. 2011;68(4):323-327. [PubMed 21289327]
- Dudley MN, McLaughlin JC, Carrington G, et al, “Oral Bacitracin vs Vancomycin Therapy for Clostridium difficile-Induced Diarrhea. A Randomized Double-Blind Trial,” Arch Intern Med, 1986, 146(6):1101-4.
- Elsner P, Pevny I, Burg G. Anaphylaxis induced by topically applied bacitracin. Am J Contact Dermat.1990;1:162-164.